The ASCO Post

Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer

The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall survival. The long-awaited findings were reported at the 2025 ASCO Annual Meeting.

Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

In the phase II Alliance A091802 trial, researchers investigated the survival benefit of adding the EGFR inhibitor to immune checkpoint inhibitor in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Surgery vs Ablation in Small Hepatocellular Carcinoma

Is surgery superior to radiofrequency ablation in the treatment of small hepatocellular carcinoma? Japanese researchers investigated.

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

Neoadjuvant anti–PD-1 plus anti–LAG-3 therapy could be effective out to 4 years for patients with advanced, resectable melanoma, study results suggest.

Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial

Learn more about a newly published 3-year follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC).

New Research Offers Reassurance About Localized Prostate Cancer Prognosis

People diagnosed with nonmetastatic low-risk prostate cancer later in life are 90% more likely to survive their cancer if they receive guideline-adherent care, reports a new study.